All In Biotech

Drug Trial Radar · NCT07587658

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy of Dupilumab Added on to Standard of Care (SOC) Treatment vs SOC Treatment Following Hospitalization for a COPD Exacerbation

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 754 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

754

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Jul 30, 2028

Study completion Jul 30, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days). The study is looking at another research question: • What side effects may happen from taking the study drug

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • dupilumabDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first all-cause eventTime frame: Through day 90
  2. Number of moderate or severe COPD exacerbationsTime frame: Through day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Inspira Medical Center Mullica Hill

    Mullica Hill, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.